Drugs / Meningococcal ACWY Conjugate Vaccine
Meningococcal ACWY Conjugate Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT01547715 | Mar 2012 → Apr 2014 | bacterial meningitis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00474526 | Mar 2007 → Sep 2008 | meningococcal meningitis | Novartis Vaccines | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00474487 Comparator | May → Aug 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal ACWY Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00474526 ↗ |
| Known as | MenACWY-CRM | “A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 75...” NCT01547715 ↗ |
| Known as | MenACWY-D | “This study compared the investigational quadrivalent meningococcal CRM₁₉₇ conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate...” PMID 20655261 ↗ Jul 2010 |
| Modality | Vaccine | “licensed quadrivalent polysaccharide (MPSV4) and conjugate (MenACWY-D) meningococcal vaccines” PMID 20655261 ↗ Jul 2010 |
| Route | Intramuscular | “administered by intramuscular injection” NCT00474487 ↗ |